Who
Charles S. Ryan
President
Company insider
Files Form 4 as: President, Quince Therapeutics; Chief Executive Officer, Neurotrope; Director, BNB Plus; Director, BioRestorative Therapies.
In numbers
- Trades disclosed
- 52
- Buys
- 3
- Sells
- 0
- Bought
- $106K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 22 Dec 2014
- Last trade
- 23 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jan 2026filed 23 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $9817,548 at $0.13 | filing |
| 18 Jun 2025filed 23 Jun 2025 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code A | $9,0587,548 at $1.20 | filing |
| 28 Jan 2025filed 11 Feb 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K48,387 at $0.65 | filing |
| 1 Feb 2024filed 2 Feb 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 1 Sep 2023filed 6 Sep 2023 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —545,000 at $0.00 | filing |
| 1 Dec 2020filed 3 Dec 2020 | Neurotropeoption or derivative | SEC FORM 4 Code D | —157,918 | filing |
| 1 Dec 2020filed 3 Dec 2020 | Neurotropeoption or derivative | SEC FORM 4 Code D | —79,097 | filing |
| 1 Dec 2020filed 3 Dec 2020 | Neurotropeoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 1 Dec 2020filed 3 Dec 2020 | Neurotropeoption or derivative | SEC FORM 4 Code D | —130,680 | filing |
| 1 Dec 2020filed 3 Dec 2020 | Neurotropeoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 24 Nov 2020filed 27 Nov 2020 | Neurotropeoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 13 Dec 2019filed 16 Dec 2019 | Neurotropeoption or derivative | SEC FORM 4 Code A | —130,680 at $0.00 | filing |
| 17 May 2019filed 21 May 2019 | BNB Plusoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —175,435 at $0.00 | filing |
| 25 Mar 2019filed 25 Mar 2019 | BRTX BioRestorative Therapiesoption or derivative · Providers & Facilities | SEC FORM 4 Code D | —15,000 | filing |
| 25 Mar 2019filed 25 Mar 2019 | BRTX BioRestorative Therapiesoption or derivative · Providers & Facilities | SEC FORM 4 Code A | —15,000 | filing |
| 25 Mar 2019filed 25 Mar 2019 | BRTX BioRestorative Therapiesoption or derivative · Providers & Facilities | SEC FORM 4 Code D | —20,000 | filing |
| 25 Mar 2019filed 25 Mar 2019 | BRTX BioRestorative Therapiesoption or derivative · Providers & Facilities | SEC FORM 4 Code A | —20,000 | filing |
News
Head-To-Head Comparison: Biorestorative Therapies (NASDAQ:BRTX) versus Kyntra Bio (NASDAQ:KYNB)BRTX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Charles S. Ryan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.